Treatment of Chronic Anal Fissure, Lateral Internal Sphincterotomy Versus Local Injection of High Dose Botulinum Toxin: A Randomized Clinical Trial
High Dose Multiple Site Injection of Botox Versus Lateral Sphincterotomy in Chronic Analfissure
Sponsors
Source
Zagazig University
Oversight Info
Has Dmc
No
Is Fda Regulated Drug
No
Is Fda Regulated Device
No
Brief Summary
comparison between the effect of lateral sphincterotomy against high dose botox injection in
chronic anal fissure the outcome was healing time, recurrence continence relapse pain
pruritus
Detailed Description
This randomized comparative clinical trial was carried out over 2 year in the period between
January 2018 and December 2019 on total number of 96 patients suffering chronic anal fissure
the participants were randomly allocated into two groups each 48 patients ; group (1) the
botulinum ( Botox) group, they were subjected to 80 IU Botox injection as an intervention for
treatment of chronic anal sphincter, and group 2 the sphincterotomy group, underwent internal
sphincterotomy as a surgical intervention for treatment of chronic anal fissure.
The study was approved by the institutional review board and the local ethical committee of
our university hospital The condition of the current study is chronic anal fissure defined as
the presence of anterior or posterior chronic anal wound with skin tag at its lower end and
hypertrophied anal papilla at its upper end with induration around its edges in patients
complaining of anal pain, constipation, and/or fresh anal bleeding for at least two months.
Randomization was achieved using computer generated cards. Inclusion criteria; patients
suffering chronic anal fissure aged above 16 years old Exclusion criteria; those with
previous anal surgery, complicated anal fissure, unfit for surgery, specific disease as
Crohn's disease and ulcerative colitis, malignancy, anal fistula or abscess those with
systemic disease requiring treatment with calcium channel blockers and /or nitrates Patients
of both groups were subjected to thorough history taking, clinical examination, digital
rectal examination and anorectal manometry for diagnosis of chronic anal fissure and
exclusion of any other anal condition and incontinence, patient signed an informed written
consent, routine preoperative investigations performed as usual.
Interventions;
1. Botulinum toxin (Botox) injection; was performed under general anesthesia in the
lithotomy position, where 80 IU of Botox was injected in four positions each 20 IU
namely in 5, 7, 11, and 1 O'clock positions in the intersphincteric space not deeper
than the midpoint of the anal canal.
2. Lateral internal sphincterotomy; was performed under general anesthesia where the lower
part of the internal sphincter was cut by electrocautery on the left lateral position to
an extent not beyond the proximal end of the fissure, the sentinel pile was also
removed.
After the procedure patients were advised for bulking agents, stool softener, and sitz baths
The follow up was carried out in the outpatient clinic by the attending surgeon (not a study
participant) after 1 week then 1, 2, 3, 6, 9 and 12 months post-procedure.
The primary outcome of the current study is complete healing of the chronic anal fissure,
recurrence in the follow up time, and development of incontinence, incontinence is described
as in (the Cleveland Clinic Florida-Fecal Incontinence (CCF-FI) scoring system), which
contains 5 questions on solid and liquid stool leakage, gas leakage, pad use, and lifestyle
restriction. the secondary outcome is postoperative or post-injection pain measured by visual
analogue scale (VAS) and the time taken for complete healing of fissure (defined as complete
epithelialization of the fissure).
Demographic data, presentation data, follow up data including primary and secondary outcome
all collected and analyzed properly using t test, chi square test, and Z test in SPSS program
22 version.
Overall Status
Completed
Start Date
2017-06-01
Completion Date
2019-05-30
Primary Completion Date
2019-05-30
Phase
N/A
Study Type
Interventional
Primary Outcome
Measure |
Time Frame |
complete healing of fissure |
2 months |
loss of anal continence |
1 week |
recurrence |
1 year |
Secondary Outcome
Measure |
Time Frame |
time taken for complete healing |
1 year |
post operative pain |
1 month |
Enrollment
96
Condition
Intervention
Intervention Type
Procedure
Intervention Name
Description
injection of 80 IU of botox in the intersphincteric space in 5,7,11 and 1 O'clock position
Arm Group Label
group 1 botox group
Intervention Type
Procedure
Intervention Name
Description
lateral internal sphincterotomy under GA in lithotomy position
Arm Group Label
group 2 lateral sphincterotomy group
Eligibility
Criteria
Inclusion Criteria:
- patients suffering chronic anal fissure aged above 16 years old
Exclusion Criteria:
- those with previous anal surgery,
- complicated anal fissure,
- unfit for surgery,
- specific disease as Crohn's disease and ulcerative colitis,
- malignancy,
- anal fistula or abscess
- those with systemic disease requiring treatment with calcium channel blockers and /or
nitrates
Gender
All
Minimum Age
16 Years
Maximum Age
N/A
Healthy Volunteers
No
Location
Facility |
Zagazig Faculty of Medicine Zagazig Sharqya 44519 Egypt |
Location Countries
Country
Egypt
Verification Date
2019-11-01
Lastchanged Date
N/A
Firstreceived Date
N/A
Responsible Party
Responsible Party Type
Principal Investigator
Investigator Affiliation
Zagazig University
Investigator Full Name
Hazem Nour Abdellatif
Investigator Title
Assistant professor
Has Expanded Access
No
Condition Browse
Number Of Arms
2
Intervention Browse
Mesh Term
Botulinum Toxins, Type A
abobotulinumtoxinA
Arm Group
Arm Group Label
group 1 botox group
Arm Group Type
Active Comparator
Description
48 patients subjected to 80 IU botox injection under GAin lithotomy position in the 5,7,11, and 1 O'clock positions
Arm Group Label
group 2 lateral sphincterotomy group
Arm Group Type
Active Comparator
Description
48 patients subjected to lateral internal sphincterotomy under GAin lithotomy position
Firstreceived Results Date
N/A
Acronym
professor
Patient Data
Sharing Ipd
Undecided
Firstreceived Results Disposition Date
N/A
Study Design Info
Allocation
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
two groups of patients randomly allocated group1 the botox group received 80 IU botox injection and group 2 under went lateral internal sphincterotomy
Primary Purpose
Treatment
Masking
Single (Participant)
Masking Description
participant don't know the procedure
Study First Submitted
November 14, 2019
Study First Submitted Qc
November 14, 2019
Study First Posted
November 18, 2019
Last Update Submitted
November 19, 2019
Last Update Submitted Qc
November 19, 2019
Last Update Posted
November 21, 2019
ClinicalTrials.gov processed this data on December 10, 2019
Conditions
Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In ClinicalTrials.gov,
conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.
Interventions
Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied.
Interventions can also include less intrusive possibilities such as surveys, education, and interviews.
Study Phase
Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions
that study is seeking to answer:
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.